134P Unmasking actionable mutations in HR+/HER2–metastatic breast cancer: Real-world insights from Avida DNA OncoLiquid BiopsyNGS combined with methylation index

Federica Bini(Ospedale Papa Giovanni XXIII), A. Zambelli(Humanitas University), Rita De Sanctis(Humanitas University), Denise Morotti(Ospedale Papa Giovanni XXIII), Vittoria Fotia(Ospedale Papa Giovanni XXIII), C Taşcă(Ospedale Papa Giovanni XXIII), Sara Licini(Ospedale Papa Giovanni XXIII), Andrea Gianatti(University of Bergamo), F. Paleni(Ospedale Papa Giovanni XXIII), E. Rota Caremoli(Ospedale Papa Giovanni XXIII), Graciela Ghirardi(Ospedale Papa Giovanni XXIII), S. Berbenni(Ospedale Papa Giovanni XXIII), Alessandra Chirco(Ospedale Papa Giovanni XXIII), M. Cardisperi(Ospedale Papa Giovanni XXIII), Nicoletta Bianchi(University of Ferrara)
ESMO Open
September 1, 2025
10.1016/j.esmoop.2025.105712
Cited by 0

Related Papers

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
|Blood|2012|270
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
|Cancer Discovery|2020|183